ABVC Cash Flow To Debt Ratio vs Cash Conversion Cycle Analysis

ABVC Stock

USD 0.47 0.01 1.06%

ABVC Biopharma financial indicator trend analysis is way more than just evaluating ABVC Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ABVC Biopharma is a good investment. Please check the relationship between ABVC Biopharma Cash Flow To Debt Ratio and its Cash Conversion Cycle accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

Cash Flow To Debt Ratio vs Cash Conversion Cycle

Cash Flow To Debt Ratio vs Cash Conversion Cycle Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ABVC Biopharma Cash Flow To Debt Ratio account and Cash Conversion Cycle. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between ABVC Biopharma's Cash Flow To Debt Ratio and Cash Conversion Cycle is -0.04. Overlapping area represents the amount of variation of Cash Flow To Debt Ratio that can explain the historical movement of Cash Conversion Cycle in the same time period over historical financial statements of ABVC Biopharma, assuming nothing else is changed. The correlation between historical values of ABVC Biopharma's Cash Flow To Debt Ratio and Cash Conversion Cycle is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Flow To Debt Ratio of ABVC Biopharma are associated (or correlated) with its Cash Conversion Cycle. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Conversion Cycle has no effect on the direction of Cash Flow To Debt Ratio i.e., ABVC Biopharma's Cash Flow To Debt Ratio and Cash Conversion Cycle go up and down completely randomly.

Correlation Coefficient

-0.04

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash Flow To Debt Ratio

Cash Conversion Cycle

Most indicators from ABVC Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ABVC Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.As of December 11, 2024, Selling General Administrative is expected to decline to about 5 M. In addition to that, Tax Provision is expected to decline to about 217.9 K

	2021	2022	2023	2024 (projected)
Other Operating Expenses	11.7M	16.1M	8.4M	4.2M
Total Revenue	355.8K	969.8K	152.4K	157.4K

Other Operating Expenses Total Revenue

ABVC Biopharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Current Liab	Current Deferred Revenue	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock	Net Receivables	Other Current Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity	Property Plant And Equipment Gross
Total Assets		0.64	0.73	0.91	0.22	-0.7	-0.05	0.17	0.5	0.78	0.78	0.68	0.57	0.63	0.63	-0.36	0.49	0.51	-0.46	0.82	0.73	0.78	0.85	0.02	-0.19	0.74
Short Long Term Debt Total	0.64		0.62	0.4	0.44	-0.3	-0.21	0.58	-0.2	0.31	0.8	0.65	0.81	0.35	0.06	-0.24	0.6	0.6	-0.26	0.69	0.64	0.23	0.4	0.02	-0.3	0.17
Total Current Liabilities	0.73	0.62		0.4	0.61	-0.62	-0.23	0.08	0.37	0.61	0.94	0.32	0.74	0.89	0.48	-0.26	0.14	0.15	-0.2	0.55	0.48	0.58	0.85	0.27	0.18	0.55
Total Stockholder Equity	0.91	0.4	0.4		-0.04	-0.63	0.08	0.06	0.56	0.74	0.45	0.64	0.31	0.34	0.65	-0.31	0.48	0.49	-0.51	0.74	0.67	0.77	0.69	-0.11	-0.38	0.75
Net Debt	0.22	0.44	0.61	-0.04		-0.31	-0.13	0.07	0.2	0.26	0.54	-0.31	0.62	0.4	0.3	0.05	-0.44	-0.44	-0.26	0.01	-0.06	0.28	0.46	0.1	-0.09	0.28
Retained Earnings	-0.7	-0.3	-0.62	-0.63	-0.31		0.2	-0.16	-0.74	-0.99	-0.56	-0.31	-0.38	-0.52	-0.72	-0.16	-0.09	-0.11	0.32	-0.52	-0.53	-0.75	-0.71	-0.33	0.26	-0.74
Common Stock Shares Outstanding	-0.05	-0.21	-0.23	0.08	-0.13	0.2		-0.21	0.08	-0.16	-0.21	-0.06	-0.24	-0.13	-0.06	-0.25	-0.05	-0.05	-0.26	-0.07	-0.04	0.02	-0.03	0.04	-0.16	0.04
Non Current Liabilities Total	0.17	0.58	0.08	0.06	0.07	-0.16	-0.21		-0.41	0.13	0.34	0.44	0.26	-0.11	-0.13	0.42	0.53	0.53	-0.13	0.21	0.24	-0.06	-0.08	0.0	-0.17	-0.08
Inventory	0.5	-0.2	0.37	0.56	0.2	-0.74	0.08	-0.41		0.77	0.19	-0.07	-0.04	0.47	0.76	-0.05	-0.33	-0.31	-0.21	0.25	0.22	0.74	0.68	0.2	-0.08	0.76
Other Stockholder Equity	0.78	0.31	0.61	0.74	0.26	-0.99	-0.16	0.13	0.77		0.57	0.37	0.37	0.52	0.77	0.08	0.15	0.16	-0.39	0.57	0.56	0.81	0.76	0.25	-0.29	0.8
Total Liab	0.78	0.8	0.94	0.45	0.54	-0.56	-0.21	0.34	0.19	0.57		0.51	0.74	0.82	0.4	-0.31	0.37	0.38	-0.22	0.64	0.57	0.54	0.79	0.25	0.09	0.5
Total Current Assets	0.68	0.65	0.32	0.64	-0.31	-0.31	-0.06	0.44	-0.07	0.37	0.51		0.41	0.22	-0.02	-0.3	0.95	0.96	-0.24	0.88	0.88	0.19	0.26	0.0	-0.22	0.13
Short Term Debt	0.57	0.81	0.74	0.31	0.62	-0.38	-0.24	0.26	-0.04	0.37	0.74	0.41		0.38	0.11	-0.09	0.29	0.29	-0.42	0.58	0.56	0.21	0.45	-0.01	-0.23	0.18
Other Current Liab	0.63	0.35	0.89	0.34	0.4	-0.52	-0.13	-0.11	0.47	0.52	0.82	0.22	0.38		0.52	-0.45	0.05	0.06	0.02	0.41	0.32	0.62	0.86	0.37	0.43	0.59
Current Deferred Revenue	0.63	0.06	0.48	0.65	0.3	-0.72	-0.06	-0.13	0.76	0.77	0.4	-0.02	0.11	0.52		-0.07	-0.16	-0.15	-0.23	0.18	0.1	0.96	0.81	0.23	-0.14	0.98
Accounts Payable	-0.36	-0.24	-0.26	-0.31	0.05	-0.16	-0.25	0.42	-0.05	0.08	-0.31	-0.3	-0.09	-0.45	-0.07		-0.26	-0.26	-0.03	-0.37	-0.27	-0.23	-0.36	-0.04	-0.09	-0.19
Cash	0.49	0.6	0.14	0.48	-0.44	-0.09	-0.05	0.53	-0.33	0.15	0.37	0.95	0.29	0.05	-0.16	-0.26		1.0	-0.15	0.7	0.71	0.03	0.05	-0.05	-0.17	-0.02
Cash And Short Term Investments	0.51	0.6	0.15	0.49	-0.44	-0.11	-0.05	0.53	-0.31	0.16	0.38	0.96	0.29	0.06	-0.15	-0.26	1.0		-0.16	0.71	0.72	0.04	0.07	-0.04	-0.18	-0.01
Common Stock	-0.46	-0.26	-0.2	-0.51	-0.26	0.32	-0.26	-0.13	-0.21	-0.39	-0.22	-0.24	-0.42	0.02	-0.23	-0.03	-0.15	-0.16		-0.29	-0.27	-0.27	-0.28	0.46	0.29	-0.27
Net Receivables	0.82	0.69	0.55	0.74	0.01	-0.52	-0.07	0.21	0.25	0.57	0.64	0.88	0.58	0.41	0.18	-0.37	0.7	0.71	-0.29		0.98	0.39	0.51	0.11	-0.31	0.33
Other Current Assets	0.73	0.64	0.48	0.67	-0.06	-0.53	-0.04	0.24	0.22	0.56	0.57	0.88	0.56	0.32	0.1	-0.27	0.71	0.72	-0.27	0.98		0.31	0.4	0.19	-0.37	0.25
Property Plant And Equipment Net	0.78	0.23	0.58	0.77	0.28	-0.75	0.02	-0.06	0.74	0.81	0.54	0.19	0.21	0.62	0.96	-0.23	0.03	0.04	-0.27	0.39	0.31		0.9	0.27	-0.18	1.0
Non Current Assets Total	0.85	0.4	0.85	0.69	0.46	-0.71	-0.03	-0.08	0.68	0.76	0.79	0.26	0.45	0.86	0.81	-0.36	0.05	0.07	-0.28	0.51	0.4	0.9		0.21	0.07	0.88
Non Currrent Assets Other	0.02	0.02	0.27	-0.11	0.1	-0.33	0.04	0.0	0.2	0.25	0.25	0.0	-0.01	0.37	0.23	-0.04	-0.05	-0.04	0.46	0.11	0.19	0.27	0.21		-0.1	0.26
Common Stock Total Equity	-0.19	-0.3	0.18	-0.38	-0.09	0.26	-0.16	-0.17	-0.08	-0.29	0.09	-0.22	-0.23	0.43	-0.14	-0.09	-0.17	-0.18	0.29	-0.31	-0.37	-0.18	0.07	-0.1		-0.18
Property Plant And Equipment Gross	0.74	0.17	0.55	0.75	0.28	-0.74	0.04	-0.08	0.76	0.8	0.5	0.13	0.18	0.59	0.98	-0.19	-0.02	-0.01	-0.27	0.33	0.25	1.0	0.88	0.26	-0.18

Click cells to compare fundamentals

ABVC Biopharma Account Relationship Matchups

ABVC Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.9M	11.6M	13.7M	9.9M	14.5M	15.2M
Short Long Term Debt Total	4.6M	6.5M	3.1M	3.1M	2.3M	1.9M
Total Current Liabilities	6.8M	4.8M	3.7M	5.8M	5.9M	6.2M
Total Stockholder Equity	(151.0K)	3.4M	8.8M	3.1M	8.4M	8.8M
Net Debt	4.4M	2.2M	(2.7M)	3.0M	2.2M	2.3M
Retained Earnings	(15.9M)	(25.6M)	(38.5M)	(54.9M)	(65.4M)	(62.1M)
Common Stock Shares Outstanding	1.7M	2.0M	2.5M	3.2M	4.3M	4.6M
Liabilities And Stockholders Equity	6.9M	11.6M	13.7M	9.9M	14.5M	15.2M
Non Current Liabilities Total	238.4K	4.1M	1.1M	420.2K	429.1K	407.7K
Inventory	(477.0K)	(839.7K)	26.0K	1.3M	1.5M	1.6M
Other Stockholder Equity	15.0M	28.5M	46.8M	57.5M	73.3M	76.9M
Total Liab	7.1M	8.9M	4.8M	6.2M	6.4M	6.7M
Total Current Assets	878.2K	6.2M	9.6M	3.0M	1.7M	1.4M
Short Term Debt	4.3M	2.4M	2.0M	2.3M	1.9M	1.3M
Other Current Liab	2.4M	2.4M	1.7M	3.3M	3.9M	4.1M
Cash	144.3K	4.3M	5.8M	85.3K	60.2K	57.1K
Cash And Short Term Investments	144.3K	4.3M	5.9M	161.1K	139.5K	132.5K
Common Stock	19.5K	24.4K	28.9K	32.9K	7.9K	7.5K
Net Receivables	640.5K	999.4K	1.7M	1.4M	759.6K	625.0K
Other Current Assets	570.4K	900.4K	1.9M	1.5M	757.7K	388.3K
Non Current Assets Total	6.0M	5.4M	4.1M	6.9M	12.8M	13.5M
Non Currrent Assets Other	179.5K	164.8K	160.5K	1.3M	1.5M	1.6M
Common Stock Total Equity	213.7K	213.9K	19.5K	24.4K	28.1K	26.7K
Accumulated Other Comprehensive Income	663.8K	564.9K	539.7K	517.1K	516.4K	396.8K
Net Tangible Assets	(5.7M)	(151.0K)	3.4M	8.8M	10.2M	10.7M
Other Assets	1.4M	1.6M	2.0M	1.1M	1.3M	1.4M
Short Long Term Debt	4.0M	2.1M	1.8M	1.9M	1.5M	2.0M
Other Liab	27.5K	2.9K	19.3K	10.6K	12.2K	11.0K
Short Term Investments	3.4M	1.2M	108.1K	75.8K	79.3K	75.3K
Long Term Investments	3.4M	1.2M	932.8K	842.1K	2.5M	1.8M
Property Plant Equipment	510.1K	1.0M	2.3M	2.0M	2.3M	2.4M
Net Invested Capital	3.9M	8.1M	10.7M	5.0M	9.9M	10.3M
Net Working Capital	(5.9M)	1.3M	5.9M	(2.8M)	(4.3M)	(4.1M)
Capital Stock	19.5K	24.4K	28.9K	32.9K	7.9K	7.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:

How To Invest In ABVC

Details

Is ABVC Stock a good investment?

Details

What is ABVC Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.81)

Revenue Per Share

0.017

Quarterly Revenue Growth

18.175

Return On Assets

(0.45)

Return On Equity

(3.20)

The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ABVC Cash Flow To Debt Ratio vs Cash Conversion Cycle Analysis

Cash Flow To Debt Ratio vs Cash Conversion Cycle

Cash Flow To Debt Ratio vs Cash Conversion Cycle Correlation Analysis

Correlation Coefficient

Cash Flow To Debt Ratio

Cash Conversion Cycle

ABVC Biopharma fundamental ratios Correlations

ABVC Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ABVC Biopharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.98	Current Deferred Revenue
Other Current Assets	+ 0.98	Net Receivables
Cash And Short Term Investments	+ 0.96	Total Current Assets
Property Plant And Equipment Net	+ 0.96	Current Deferred Revenue

Other Stockholder Equity	- 0.99	Retained Earnings
Property Plant And Equipment Net	- 0.75	Retained Earnings
Property Plant And Equipment Gross	- 0.74	Retained Earnings
Inventory	- 0.74	Retained Earnings
Current Deferred Revenue	- 0.72	Retained Earnings
Non Current Assets Total	- 0.71	Retained Earnings